Sugi Predict

Sugi Predict / Compounds / SCHEMBL2592300

SCHEMBL2592300

SCHEMBL2592300

O=S(=O)(O)c1ccccc1-c1cccc(P)c1-c1ccccc1S(=O)(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGAM1 P18669 1/20 0.44
▸ NFKB1 P19838 2/20 0.38
▸ KDM4A O75164 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ NSD2 O96028 1/20 0.38
▸ ALPL P05186 1/20 0.38
▸ PLCG1 P19174 1/20 0.38
▸ TNNI3 P19429 1/20 0.38
▸ TNNT2 P45379 1/20 0.38
▸ MMP14 P50281 1/20 0.38
▸ CASP6 P55212 1/20 0.38
▸ TNNC1 P63316 1/20 0.38
▸ KDM4C Q9H3R0 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ TTR P02766 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ MAPT P10636 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ GNG2 P59768 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8145542 0.98 PGAM1 (0.42) PGAM1NFKB1KDM4AUSP2NSD2
Water SCHEMBL3801022 0.96 PGAM1 (0.41) PGAM1NFKB1KDM4AUSP2NSD2
SCHEMBL2593808 0.86 PGAM1 (0.40) PGAM1NFKB1KDM4AUSP2NSD2
SCHEMBL458284 0.82 SMN1; SMN2 (0.48) PGAM1NFKB1KDM4AUSP2NSD2
SCHEMBL28837581 0.80 SMN1; SMN2 (0.46) PGAM1NFKB1KDM4AUSP2NSD2
Phosphine SCHEMBL2593813 0.79 PGAM1 (0.41) PGAM1NFKB1KDM4AUSP2NSD2
SCHEMBL24631331 0.78 TTR (0.47) PGAM1TTRALDH1A1SMN1; SMN2MAPT
SCHEMBL31021957 0.78 TSHR (0.44) PGAM1NSD2CASP6L3MBTL1TTR
SCHEMBL845825 0.78 TSHR (0.44) PGAM1NSD2CASP6L3MBTL1TTR
SCHEMBL9763220 0.77 MAPT (0.52) PGAM1NFKB1KDM4AUSP2NSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11740233-B2 Antibody-nanoparticle conjugates and methods for making and using such conjugates VENTANA MEDICAL SYSTEMS, INC. (US) 2023-08-29 — — US claimed
US-20180372733-A1 ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR MAKING AND USING SUCH CONJUGATES VENTANA MED SYST INC (US) 2018-12-27 — — US claimed
EP-2564203-A2 ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR MAKING AND USING SUCH CONJUGATES Ventana Medical Systems, Inc. (US) 2013-03-06 — — EP claimed
WO-2011139792-A2 ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR MAKING AND USING SUCH CONJUGATES VENTANA MEDICAL SYSTEMS, INC. (US) 2011-11-10 — — WO claimed
EP-0715890-B1 Electrochemical preparation process of transition metal and phosphine containing catalysts RHONE POULENC FIBRES (FR) 1999-09-22 — — EP claimed
EP-0647619-B1 Process for the preparation of 2-methyl-3-butene nitrile RHONE POULENC FIBRES (FR) 1998-05-20 — — EP claimed
US-5679237-A ELECTROLYZING AQUEOUS SOLUTION CATHOLYTE CONTAINING TRANSITION METAL COMPOUND AND SULFONATED PHOSPHINE R. P. FIBER & RESIN INTERMEDIATES (FR) 1997-10-21 — — US claimed
EP-0650959-B1 Hydrocyanation process of unsatured nitriles into dinitriles RHONE POULENC CHIMIE (FR) 1997-09-03 — — EP claimed
EP-0722432-A1 METHOD FOR PREPARING OF MONO OR DI-2-SUBSTITUTED CYCLOPENTANONE RHONE-POULENC AGROCHIMIE (FR) 1996-07-24 — — EP claimed
US-5488129-A CATALYST SYSTEM CONTAINING TRANSITION METAL COMPOUND, SULFONATED PHOSPHINE, LEWIS ACID RHONE-POULENC CHIMIE (FR) 1996-01-30 — — US claimed
US-5486643-A Isomerization of 2-methyl-3-butenenitrile RHONE-POULENC CHIMIE (FR) 1996-01-23 — — US claimed
WO-1995009830-A1 METHOD FOR PREPARING OF MONO OR DI-2-SUBSTITUTED CYCLOPENTANONE RHONE POULENC AGROCHIMIE (FR) 1995-04-13 — — WO claimed
US-12606512-B2 Process for the hydroformylation of olefins in homogeneous phase OXEA GMBH (DE) 2026-04-21 — — US disclosed
US-12503418-B2 Process for the preparation of polycyclic aliphatic dialdehydes OXEA GMBH (DE) 2025-12-23 — — US disclosed
EP-4008710-B1 METHOD FOR HYDROFORMYLATION OF OLEFINS IN THE HOMOGENEOUS PHASE OQ CHEMICALS GMBH (DE) 2024-05-01 — — EP disclosed
EP-4008709-B1 METHOD FOR THE PREPARATION OF POLYCYCLIC ALIPHATIC DIALDEHYDES OQ CHEMICALS GMBH (DE) 2024-05-01 — — EP disclosed
WO-1995009830-A1 METHOD FOR PREPARING OF MONO OR DI-2-SUBSTITUTED CYCLOPENTANONE RHONE POULENC AGROCHIMIE (FR) 1995-04-13 — — WO disclosed
US-RE31812-E TO ALDEHYDES IN PRESENCE OF CATALYTIC SYSTEM CONTAINING RHODIUM AND SULFONATED ARYL PHOSPHINE COMPOUND RHONE-POULENC INDUSTRIES (FR) 1985-01-22 — — US disclosed
US-4248802-A Catalytic hydroformylation of olefins RHONE-POULENC INDUSTRIES (FR) 1981-02-03 — — US disclosed
US-4142060-A DIENES, WATER RHONE-POULENC INDUSTRIES (FR) 1979-02-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503418-B2 Process for the preparation of polycyclic aliphatic dialdehydes DDT, SHARPIN, DBF4 PGAM1 687/4885NFKB1 2483/4885KDM4A 2426/4885
US-12606512-B2 Process for the hydroformylation of olefins in homogeneous phase HMOX1, HAO2, AQP1 PGAM1 1103/4885NFKB1 1791/4885KDM4A 3216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.